High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department

Consorci Sanitari de l'Alt Penedès i Garraf

Status: Not yet enrolling

Conditions: Acute Disease

Treatments: Other: Antithrombotic therapy

Study type: Observational

Funder types: Other

Identifiers

NCT07278648

CSAPG-79

Details and patient eligibility

About

This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or hemorrhagic event related to the treatment.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients discharged from the Emergency Department (ED) and acute care units with an electronic prescription for at least one anticoagulant medication (new or ongoing), identified with the following codes:

B01AA - Vitamin K antagonists: warfarin and acenocoumarol

B01AB - Heparin group: low-molecular weight heparins such as enoxaparin, tinzaparin, bemiparin, …

B01AE - Direct thrombin inhibitors: dabigatran

B01AF - Direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban

Exclusion criteria

• Those who are not part of the CSAPG healthcare area.
• Patients discharged from outpatient clinics, home hospitalization units, intermediate care, or residential facilities.

Trial design

150 participants in 1 patient group

Anticoagulant therapy

Description:

Patients who has been discharged from hospital with anticoagulant therapy

Treatment:

Other: Antithrombotic therapy